U.S. pharma huge copyright scrapped two experimental weight loss supplements last year—a after-day-to-day tablet, lotiglipron, on account of elevated liver enzymes plus a two times-daily tablet, danuglipron, due to solid side effects—but CEO Albert Bourla has reported the company is set to “Enjoy and gain” from the weight problems Area As w